Saturday, July 11, 2026

Drug profile · INN

rivoceranib

rivoceranib is a vascular endothelial growth factor receptor 2 inhibitor.

NMPA: clinical trials
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — rivoceranib
Class
Route
Patents
0
Programs
0
Data quality
0.70

Quick answer

rivoceranib is a vascular endothelial growth factor receptor 2 inhibitor.

Key facts

INN rivoceranib
Mechanism Vascular endothelial growth factor receptor 2 inhibitor

Mechanism of action

Vascular endothelial growth factor receptor 2 inhibitor

Approval history

Authority Status Date
NMPA clinical trials

Frequently asked questions

What is rivoceranib?

rivoceranib is a vascular endothelial growth factor receptor 2 inhibitor.